New Emapalumab Data Presented at Transplantation and Cellular Therapy (TCT) Meeting Highlight Post-transplant Treatment Outcomes in Primary HLH

STOCKHOLM, Feb. 26, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) at the 2019...

from PR Newswire: https://ift.tt/2tBeyeG